Related Experiment Videos
Triazine derivatives inhibit rat hepatocarcinogenesis but do not enhance gap junctional intercellular communication
T Hori1, M Asamoto, V Krutovskikh
1Chemotherapy Division, National Cancer Center Research Institute, Chuo-ku, Tokyo.
Abstract:
We report here novel candidate chemopreventive agents active against experimental hepatocarcinogenesis. The triazine derivatives 6-(2-chlorophenyl)-2,4-diamino-1,3,5-triazine (2CPDAT), 6-(3-chlorophenyl)-2,4-diamino-1,3,5-triazine (3CPDAT), 6-(4-chlorophenyl)-2,4-diamino-1,3,5-triazine (4CPDAT), 6-(4-pyridyl)-2,4-diamino-1,3,5-triazine (PyDAT), and 6-(pyridine N-oxid-4-yl)-2,4-diamino-1,3,5-triazine (PyNODAT), synthesized in our laboratory, in addition to 6-(2,5-dichloro-phenyl)-2,4-diamino-1,3,5-triazine (DCPDAT), or irsogladine, which is a widely used anti-ulcer drug, were investigated for potential chemopreventive effects in a rat liver medium-term bioassay system. A significant inhibitory influence on enzyme-altered liver foci was found for 2CPDAT, 3CPDAT, 4CPDAT, and PyNODAT, but not for DCPDAT or PyDAT. The involvement of gap junctional intercellular communication in the inhibition was studied, but no change in gap junctional intercellular communication capacity in rat liver cells in vitro or in gap junction protein (connexin 32) expression in rat liver in vivo was noted. These results indicate that, although these irsogladine analogues exert inhibitory effects on rat liver carcinogenesis, their action is independent of modification of gap junctional intercellular communication.
Insights
Novel triazine derivatives show promise as chemopreventive agents against experimental liver cancer. These compounds, including specific chlorophenyl and pyridyl triazines, inhibited cancer development in rats, independent of gap junction communication.
Area of Science:
- Hepatocarcinogenesis research
- Chemoprevention strategies
- Medicinal chemistry of triazine derivatives
Background:
- Experimental hepatocarcinogenesis models are crucial for evaluating potential cancer-preventive agents.
- Triazine derivatives, including the anti-ulcer drug irsogladine, represent a class of compounds with potential therapeutic applications.
- Understanding the mechanisms of chemoprevention is vital for developing effective cancer therapies.
Purpose of the Study:
- To investigate the chemopreventive effects of novel triazine derivatives against experimental rat liver cancer.
- To evaluate the role of gap junctional intercellular communication (GJIC) in the chemopreventive action of these agents.
- To identify specific structural features of triazine derivatives that contribute to their efficacy.
Main Methods:
- Synthesis of novel triazine derivatives: 2CPDAT, 3CPDAT, 4CPDAT, PyDAT, PyNODAT, and DCPDAT (irsogladine).
- Medium-term rat liver bioassay to assess chemopreventive effects on enzyme-altered liver foci.
- In vitro and in vivo studies to evaluate changes in gap junctional intercellular communication capacity and connexin 32 expression.
Main Results:
- Significant inhibition of enzyme-altered liver foci was observed for 2CPDAT, 3CPDAT, 4CPDAT, and PyNODAT.
- DCPDAT (irsogladine) and PyDAT did not show significant chemopreventive effects in this model.
- No alterations in gap junctional intercellular communication capacity or connexin 32 expression were detected, indicating an alternative mechanism of action.
Conclusions:
- Several novel triazine derivatives demonstrate significant chemopreventive activity against experimental hepatocarcinogenesis in rats.
- The chemopreventive effects of these irsogladine analogues are independent of modulation of gap junctional intercellular communication.
- These findings highlight the potential of specific triazine derivatives as candidates for further development as chemopreventive agents for liver cancer.